- Long-term follow-up results confirm benefits of calcium channel blockers (CCBs) plus statins in protection against cardiovascular disease (CVD)-related, all-cause mortality.
- The ASCOT Legacy study is a 16-year follow-up of the original ASCOT trial .
Why this matters
- These authors say that this work is the first report showing long-term benefit of the combination of antihypertensives and statins.
- 36.9% of deaths were CVD-related.
- With antihypertensives only, fewer stroke-related deaths with CCB vs beta-blocker:
- aHR, 0.71; 95% CI, 0.53-0.97; P=.0305.
- CCB also bested beta-blocker in nonstatin group in statin/placebo portion of trial:
- Fewer cardiovascular deaths: aHR, 0.79 (95% CI, 0.67-0.93; P=.0046).
- Fewer coronary heart disease deaths: aHR, 0.76 (95% CI, 0.59-0.93; P=.0439).
- Patients receiving antihypertensive plus statin had reduced CVD-related deaths:
- HR, 0.85; 95% CI, 0.72-0.99; P=.0395.
- Analysis of participants (total for current study, 7302) from the ASCOT trial, which started 16 years ago.
- ASCOT was multicenter, randomized, with 2×2 factorial design:
- All patients in BP-lowering arm had either CCB or beta-blocker.
- Those with low total cholesterol and no lipid-reducing treatment were further included in statin/placebo portion of trial.
- Funding: Pfizer.
- No data on nonfatal CVD outcomes or medications taken after the trial ended.
- Limited to UK residents.